TME Therapeutics Inc.

TME Therapeutics Inc.

About Us

Research and development

News

Latest News

2022.6.2

Final results from Phase 1/2a clinical study of STNM01 as a second-line therapy for unresectable pancreatic cancer were presented by Dr. Tsuchiya at American Society of Clinical Oncology (ASCO) annual meeting 2022.

https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4144


2022.6.2

Results from preclinical study were presented by Dr. Ye at American Society of Clinical Oncology (ASCO) annual meeting 2022.
Title: Effect of silencing tumoral carbohydrate sulfotransferase 15 on T cells in a murine model of pancreatic cancer.

https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e16241


2022.5.22

Results from preclinical study were presented by Dr. Ye at Digestive Disease Week (DDW) annual meeting 2022.
Title: Silencing of tumoral carbohydrate sulfotransferase 15 augments tumor-infiltrating T cells with boosted lymph node T cell priming in a murine model of pancreatic cancer

SILENCING OF TUMORAL CARBOHYDRATE SULFOTRANSFERASE 15 AUGMENTS…. DDW ePoster Library. Ye J. May 22 2022; 354739


2022.5.21

Final results from Phase 1/2a clinical study of STNM01 as a second-line therapy for unresectable pancreatic cancer were presented by Dr. Tanisaka at Digestive Disease Week (DDW) annual meeting 2022.
Title: Locoregional injection of the RNA oligonucleotide targeting carbohydrate sulfotransferase 15 is able to accelerate tumor-infiltrating T cells in patients with unresectable pancreatic cancer, refractory to first-line chemotherapy

LOCOREGIONAL INJECTION OF THE RNA OLIGONUCLEOTIDE TARGETING…. DDW ePoster Library. Tanisaka Y. May 21 2022; 352839


2021.6.4

Top-line results from Phase 1/2a clinical study of STNM01 as a second-line therapy for unresectable pancreatic cancer were presented by Dr. Tsuchiya at American Society of Clinical Oncology (ASCO) annual meeting 2021.
Title: A phase I/IIa trial of the RNA oligonucleotide STNM01 by EUS-FNI to investigate the safety and efficacy in patients with first-line refractory, unresectable pancreatic cancer.

https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.4120